Technique to Make CAR T-Cells In Vivo Could Transform Cancer Care

Context: 

• A new in vivo CAR T-cell therapy method shows potential in transforming cancer and autoimmune care by simplifying production and reducing risks and costs associated with traditional CAR T-cell approaches.

Key Highlights: 

• A new method enables engineering of CAR T-cells inside the body using mRNA-loaded lipid nanoparticles (LNPs).
• Avoids ex vivo cell processing, viral vectors, and lymphodepleting chemotherapy.
• In preclinical trials on mice and monkeys, the method showed effective tumour regression and B-cell depletion.
• Uses CD8-targeted lipid nanoparticles (CD8-tLNPs) for precise delivery to immune cells.
• Could significantly reduce costs, making therapy accessible in low-resource settings like India.
• Potential to treat autoimmune diseases by resetting the immune system.

Detailed Insights:

• Traditional CAR T-cell therapy is highly personalised, involving cell harvesting, genetic modification, and hospital-based chemotherapy, costing ₹60–70 lakh in India.
• The new in vivo method bypasses these steps by using mRNA to directly reprogram CD8+ T cells inside the body.
• Avoidance of lymphodepletion reduces infection risks and hospital stays.
• The treatment led to temporary B-cell depletion, followed by repopulation with naïve B cells, mirroring immune resets seen in autoimmune patients.
• Early lab tests on blood from lupus and myositis patients confirmed T-cell reprogramming in vitro.
• Side effects were generally mild, though one monkey developed serious immune overreaction, highlighting the need for dose monitoring.
• The standardised, infusion-based method resembles biologic drug administration rather than complex cell therapy.
• Experts stress the need for robust human trials to assess reproducibility, long-term effects, and scalability.
• Could greatly benefit India, where B-cell cancers and autoimmune disorders are rising and cell therapy access is limited.

Scientific/Technical Concepts Involved

• CAR T-cell Therapy: A form of immunotherapy where T cells are modified to express Chimeric Antigen Receptors (CARs) that target cancer cells.
• mRNA Therapy: Uses messenger RNA to deliver genetic instructions to cells temporarily.
• Lipid Nanoparticles (LNPs): Fat-based carriers used for targeted delivery of genetic material.
• CD8+ T cells: Cytotoxic T cells responsible for killing infected or abnormal cells.
• Lymphodepletion: Pre-treatment that clears existing immune cells, often with side effects.